Se connecter pour consulter les tarifs organisationnels et contractuels.
Sélectionner une taille de conditionnement
Changer de vue
A propos de cet article
Formule empirique (notation de Hill) :
C22H43N5O13
Numéro CAS:
Poids moléculaire :
585.60
MDL number:
UNSPSC Code:
41116107
EC Number:
253-538-5
NACRES:
NA.24
Service technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aidergrade
pharmaceutical primary standard
API family
amikacin
manufacturer/tradename
EDQM
application(s)
pharmaceutical (small molecule)
format
neat
SMILES string
N([C@H]1[C@@H]([C@H]([C@@H]([C@H](C1)N)O[C@H]3O[C@@H]([C@H]([C@@H]([C@H]3O)O)O)CN)O)O[C@H]2O[C@@H]([C@H]([C@@H]([C@H]2O)N)O)CO)C(=O)[C@@H](O)CCN
InChI
1S/C22H43N5O13/c23-2-1-8(29)20(36)27-7-3-6(25)18(39-22-16(34)15(33)13(31)9(4-24)37-22)17(35)19(7)40-21-14(32)11(26)12(30)10(5-28)38-21/h6-19,21-22,28-35H,1-5,23-26H2,(H,27,36)/t6-,7+,8-,9+,10+,11-,12+,13+,14+,15-,16+,17-,18+,19-,21+,22+/m0/s1
InChI key
LKCWBDHBTVXHDL-RMDFUYIESA-N
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.
Application
Amikacin EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
Packaging
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
Other Notes
Sales restrictions may apply.
Faites votre choix parmi les versions les plus récentes :
Déjà en possession de ce produit ?
Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.
A Bruce Montgomery et al.
Antimicrobial agents and chemotherapy, 58(7), 3714-3719 (2014-04-23)
The amikacin-fosfomycin inhalation system (AFIS) is a combination of 2 antibiotics and an in-line nebulizer delivery system that is being developed for adjunctive treatment of pneumonia caused by Gram-negative organisms in patients on mechanical ventilation. AFIS consists of a combination
M P Goren et al.
The Pediatric infectious disease journal, 8(5), 278-282 (1989-05-01)
A three-drug antibiotic regimen including vancomycin and amikacin has been recommended as effective treatment in clinical settings in which Gram-positive bacteremias are a serious problem. To determine if vancomycin potentiates the tubular proteinuria associated with amikacin therapy, we studied febrile
Sophia B Georghiou et al.
PloS one, 7(3), e33275-e33275 (2012-04-06)
Rapid molecular diagnostics for detecting multidrug-resistant and extensively drug-resistant tuberculosis (M/XDR-TB) primarily identify mutations in Mycobacterium tuberculosis (Mtb) genes associated with drug resistance. Their accuracy, however, is dependent largely on the strength of the association between a specific mutation and